Express Scripts, one of the largest pharmacy benefit managers in the country, will cover AbbVie's new hepatitis C treatment and will no longer cover Gilead Sciences treatments, according to a Reuters report.
Express Scripts has opposed the price of Gilead Sciences' Sovaldi treatment — $84,000 — since it was approved. The pharmacy benefits manager said that it was unaffordable. AbbVie's Viekira Pak drug, recently approved by the U.S. Food and Drug Administration, has a significantly lower price, Express Scripts CMO Steve Miller.
More articles on gastroenterology:
Adopting the updated GI procedure quality metrics & what this means for practice
Making the most of 2015: New Year’s resolutions in GI
10 most-read GI/endoscopy stories of 2014